Prevalence and Characteristics of Breakthrough Pain in Patients with Head and Neck Cancer: A Cross-Sectional Study

被引:20
作者
Bhatnagar, Sushma [1 ]
Upadhyay, Surjya [1 ]
Mishra, Seema [1 ]
机构
[1] All India Inst Med Sci, Inst Rotary Canc Hosp, Dept Anaesthesia, New Delhi 110016, India
关键词
RELEASE MORPHINE-SULFATE; LOW-BACK-PAIN; IMMEDIATE-RELEASE; PALLIATIVE-CARE; HYDROMORPHONE; DEFINITION; INTENSITY; EFFICACY; TABLET;
D O I
10.1089/jpm.2009.0266
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Approximately one half to two thirds of patients with cancer-related pain experience breakthrough pain (BTP) in their daily activities. Objective: This is the first report to determine the prevalence and characteristics of BTP experienced by patients with head and neck cancer. Methods: This was a prospective cross-sectional study conducted in patients with head and neck cancer on stable doses of opioid (morphine) for at least 1 week. This study was designed as a cross-sectional study using a series of breakthrough pain questionnaires (BPQ). Results: Prevalence of BTP in our study was 48% (average of 3.85 episodes per day) of which more than 50% of episodes were of gradual onset but with severe intensity. Incident pain was predominate (50%) followed by spontaneous (25%) and end of dose failure (20%) and in 5% the nature of pain was unknown or mixed. Unlike other studies the onset of BTP in this present study with head and neck cancer was more gradual and lasted longer than 30 minutes. Conclusions: Patients with head and neck cancer do suffer a lot because of the high incidence of BTP (48%). The majority of patients suffering from BTP are not satisfied at all with the measures taken for their BTP. The majority of patients in India have head and neck cancer; we must approach this matter as a challenge and new technique and therapy should be introduced for the benefit of these patients.
引用
收藏
页码:291 / 295
页数:5
相关论文
共 23 条
[1]  
Bennett D., 2005, P T, V30, P354
[2]   Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey [J].
Caraceni, A ;
Martini, C ;
Zecca, E ;
Portenoy, RK .
PALLIATIVE MEDICINE, 2004, 18 (03) :177-183
[3]   Breakthrough cancer pain:: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®) [J].
Coluzzi, PH ;
Schwartzberg, L ;
Conroy, JD ;
Charapata, S ;
Gay, M ;
Busch, MA ;
Chavez, J ;
Ashley, J ;
Lebo, D ;
McCracken, M ;
Portenoy, RK .
PAIN, 2001, 91 (1-2) :123-130
[4]   Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale [J].
Farrar, JT ;
Young, JP ;
LaMoreaux, L ;
Werth, JL ;
Poole, RM .
PAIN, 2001, 94 (02) :149-158
[5]   PLACEBO-BLINDED STUDY OF MORPHINE-SULFATE SUSTAINED-RELEASE TABLETS AND IMMEDIATE-RELEASE MORPHINE-SULFATE SOLUTION IN OUTPATIENTS WITH CHRONIC PAIN DUE TO ADVANCED CANCER [J].
FINN, JW ;
WALSH, TD ;
MACDONALD, N ;
BRUERA, E ;
KREBS, LU ;
SHEPARD, KV .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) :967-972
[6]   Breakthrough cancer pain:: Prevalence and characteristics in patients in Catalonia, Spain [J].
Gómez-Batiste, X ;
Madrid, F ;
Moreno, F ;
Gracia, A ;
Trelis, J ;
Nabal, M ;
Alcalde, R ;
Planas, J ;
Camell, H .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 24 (01) :45-52
[7]  
Gutgsell Terence, 2003, Am J Hosp Palliat Care, V20, P140, DOI 10.1177/104990910302000213
[8]  
HAYS H, 1994, CANCER-AM CANCER SOC, V74, P1808, DOI 10.1002/1097-0142(19940915)74:6<1808::AID-CNCR2820740625>3.0.CO
[9]  
2-Y
[10]   Cancer breakthrough pain characteristics and responses to treatment at a VA medical center [J].
Hwang, SS ;
Chang, VT ;
Kasimis, B .
PAIN, 2003, 101 (1-2) :55-64